Oramed Pharmaceuticals Inc.

Historical 13F Holders

Symbol
ORMP
CUSIP
68403P203
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 68403P203 since 12/18/2024, largest first.

Filer % of Class Filed
Nadav Kidron 13D/A 7.6% 8/28/2025
Event 2/11/2025
Aquamarine Financial (Cayman) Ltd 13G/A 6.0% 8/14/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (1)
BML Investment Partners, L.P. 13G/A
2.5% 6/29/2026
Event 6/26/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 12 96.1 k $441 k
2026 Q2 85 16.8 M $80.7 M
2026 Q1 65 13.5 M $45.8 M
2025 Q4 59 13.3 M $38.0 M
2025 Q3 48 9.21 M $24.3 M
2025 Q2 51 7.30 M $16.4 M
2025 Q1 55 7.77 M $16.6 M
2024 Q4 59 7.67 M $18.6 M
2024 Q3 57 6.96 M $17.0 M
2024 Q2 61 5.99 M $15.4 M
2024 Q1 56 5.36 M $15.7 M
2023 Q4 61 5.25 M $12.1 M
2023 Q3 58 2.30 M $5.99 M
2023 Q2 54 2.28 M $8.16 M
2023 Q1 65 4.26 M $9.30 M
2022 Q4 86 3.65 M $43.8 M
2022 Q3 77 3.94 M $25.5 M
2022 Q2 94 6.69 M $31.0 M
2022 Q1 115 9.07 M $78.5 M
2021 Q4 133 8.75 M $125 M
2021 Q3 103 5.41 M $119 M
2021 Q2 83 3.84 M $51.4 M
2021 Q1 52 1.30 M $64.8 M
2020 Q4 45 1.46 M $6.19 M
2020 Q3 37 2.00 M $5.19 M
2020 Q2 38 1.35 M $4.73 M
2020 Q1 35 639 k $1.97 M
2019 Q4 36 641 k $3.30 M
2019 Q3 31 760 k $2.43 M
2019 Q2 27 839 k $3.01 M
2019 Q1 26 1.07 M $3.91 M
2018 Q4 31 1.90 M $5.76 M
2018 Q3 30 1.76 M $8.56 M
2018 Q2 22 281 k $2.09 M
2018 Q1 22 301 k $2.01 M
2017 Q4 27 378 k $3.40 M
2017 Q3 23 276 k $2.73 M
2017 Q2 25 180 k $1.35 M
2017 Q1 24 162 k $995 k
2016 Q4 26 156 k $952 k
2016 Q3 24 182 k $1.32 M
2016 Q2 29 291 k $2.43 M
2016 Q1 29 201 k $1.32 M
2015 Q4 30 210 k $1.78 M
2015 Q3 20 157 k $855 k
2015 Q2 18 335 k $1.91 M
2015 Q1 18 544 k $3.37 M
2014 Q4 24 1.00 M $5.61 M
2014 Q3 20 1.38 M $11.1 M
2014 Q2 25 1.43 M $13.7 M
2014 Q1 24 1.31 M $15.3 M